Meerarani P, Moreno P R, Cimmino G, Badimon J J
Zena and Michael A. Wiener Cardiovascular Institute and The Marie-Jose and Henry R. Kravis Cardiovascular Health Center, The Mount Sinai School of Medicine, New York, 10029 NY., USA.
Indian J Exp Biol. 2007 Jan;45(1):103-10.
Atherothrombotic vascular disease is a complex disorder in which inflammation and coagulation play a pivotal role. Rupture of high-risk, vulnerable plaques with the subsequent tissue factor (TF) exposure is responsible for coronary thrombosis, the main cause of unstable angina, acute myocardial infarction, and sudden cardiac death. Tissue factor (TF), the key initiator of coagulation is an important modulator of inflammation. TF is widely expressed in atherosclerotic plaques and found in macrophages, smooth muscle cells, extracellular matrix and acellular lipid-rich core. TF expression can be induced by various stimulants such as C-reactive protein, oxLDL, hyperglycemia and adipocytokines. The blood-born TF encrypted on the circulating microparticles derived from vascular cells is a marker of vascular injury and a source of procoagulant activity. Another form of TF, called alternatively spliced has been recently identified in human and murine. It is soluble, circulates in plasma and initiates coagulation and thrombus propagation. Evidence indicates that elevated levels of blood-borne or circulating TF has been associated with metabolic syndrome, type 2 diabetes and cardiovascular risk factors and is a candidate biomarker for future cardiovascular events. Therapeutic strategies have been developed to specifically interfere with TF activity in the treatment of cardiovascular disease.
动脉粥样硬化血栓形成性血管疾病是一种复杂的病症，其中炎症和凝血起着关键作用。高危易损斑块破裂并随后暴露组织因子（TF）会导致冠状动脉血栓形成，这是不稳定型心绞痛、急性心肌梗死和心源性猝死的主要原因。组织因子（TF）作为凝血的关键启动因子，是炎症的重要调节因子。TF在动脉粥样硬化斑块中广泛表达，存在于巨噬细胞、平滑肌细胞、细胞外基质和富含无细胞脂质的核心中。TF表达可由多种刺激物诱导，如C反应蛋白、氧化低密度脂蛋白、高血糖和脂肪细胞因子。源自血管细胞的循环微粒上携带的血源性TF是血管损伤的标志物和促凝活性的来源。最近在人和小鼠中发现了另一种形式的TF，称为可变剪接TF。它是可溶的，在血浆中循环并启动凝血和血栓形成。有证据表明，血源性或循环TF水平升高与代谢综合征、2型糖尿病和心血管危险因素相关，并且是未来心血管事件的候选生物标志物。已经开发出治疗策略来特异性干扰TF活性以治疗心血管疾病。
